Correlogic Systems Obtains CE Mark for OvaCheck®

Wednesday, June 9, 2010 Drug News
Email Print This Page Comment bookmark
Font : A-A+

GERMANTOWN, Md., June 9 Correlogic Systems, Inc. announced today that OvaCheck, the company's blood test for the detection of epithelial ovarian cancer, has fulfilled European Union regulatory requirements (CE marking) for distribution and sale of the test. The path is now cleared for the test to be made available to patients in Europe through their physicians.

OvaCheck is a cutting-edge multivariate index assay that measures the relative ratios of eight proteins. It employs a bead-based multiplexed immunoassay platform and Correlogic's proprietary software system to return a result. The simple blood test will help physicians more accurately determine whether a pelvic mass is ovarian cancer -- leading to earlier, appropriate treatment and fewer unnecessary surgeries.

Ovarian cancer is the most deadly gynecologic cancer, in significant part because detection has been difficult and the disease is overwhelmingly detected when it is advanced. Europe has among the highest incidence rates of ovarian cancer in the world.

"Accurate detection of ovarian cancer has been elusive, but it is essential to saving lives," said Peter Levine, CEO of Correlogic. "OvaCheck can be a powerful tool for earlier, more accurate detection of ovarian cancer without an invasive procedure -- a real advancement in confronting this disease."

Correlogic is currently in discussions with potential partners for distribution of OvaCheck in Europe.

About Correlogic Systems, Inc. Correlogic Systems, Inc. has pioneered the use of pattern recognition technologies for the development of proteomic, metabolomic and genomic based clinical prognostic and clinical diagnostic tests. The company has applied its proprietary software and sample preparation technologies to a wide range of high throughput bioassay platforms, including mass spectrometry, nuclear magnetic resonance spectrometry, nucleic acid arrays, and immunoassays. Correlogic's technologies have a wide range of applications for the creation of disease classification models, biomarker discovery, and new drug discovery processes. Correlogic's research, demonstrating results in cancer and non-cancer disease research, drug discovery, drug response monitoring, bio-security and other applications has been published in 18 peer-reviewed journals. Emergo Europe is Correlogic's Authorized Representative for OvaCheck in Europe. Visit Correlogic at

Cautionary Statement: Certain statements contained in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results could differ materially due to, among other things, operational and other difficulties associated with integrating acquired business, general business conditions, competition among managed care companies, rising health costs, trends in medical loss ratios, health care reform, delay in receipt of regulatory and other approvals for pending transactions and other regulatory issues.

SOURCE Correlogic Systems, Inc.

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store